Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Year range
J Clin Med ; 11(11)2022 May 31.
Article in English | MEDLINE | ID: covidwho-1869672


While the relative efficacy of remdesivir as a therapeutic agent in selected patients with COVID-19 has been established, safety concerns have been raised regarding potential nephrotoxicity and hepatotoxicity. Our main objective was to investigate the kidney- and liver-related safety outcomes in patients with COVID-19 treated with remdesivir in a public hospital in New York. A propensity score-matched retrospective study was conducted in hospitalized patients with COVID-19 from 1 June 2020 to 10 March 2021. A total of 927 patients were included in this study (remdesivir: 427, non-remdesivir: 500; women: 51.8%; median age 61 years; median BMI: 28.5 kg/m2). Matching without replacement yielded a cohort of 248 patients (124 in each group). In the matched cohort, the remdesivir group had a significantly lower rate of acute kidney injury (AKI) (12.1% vs. 21.8%, p = 0.042), a lower rate of acute liver injury (ALI) on the verge of statistical significance (7.3% vs. 14.5%, p = 0.067), and non-significantly lower death rate (13.7% vs. 16.1%, p = 0.593) compared to the non-remdesivir group. Multivariable analyses revealed that patients treated with remdesivir were found to be associated with a significantly lower likelihood for AKI (OR: 0.40; 95% CI: 0.24-0.67, p < 0.001), no association was found for ALI (OR: 0.68; 95% CI: 0.35-1.30, p = 0.241), while a trend towards an association of patients treated with remdesivir with a lower likelihood for in-hospital death was observed (OR: 0.57; 95% CI: 0.32-1.01, p = 0.053). In conclusion, no safety concerns with regards to renal and liver outcomes were raised in patients with COVID-19 treated with remdesivir. Instead, there were signals of possible nephroprotection and improved in-hospital mortality.

Non-conventional in English | Homeland Security Digital Library, Grey literature | ID: grc-740902


From the Document: [1] On May 13, 2020, Brookings India organised a Foreign Policy & Security Studies webinar panel discussion, 'Will COVID [coronavirus disease 2019] reverse regional connectivity? Perspectives from South Asia.' [2] The panel featured Munir Khasru, Chairman, Institute for Policy, Advocacy, and Governance, Bangladesh;Dr. Dinusha Panditaratne, Non-Resident Fellow, Lakshman Kadirgamar Institute, Sri Lanka;Dr. George Varughese, Senior Strategic Advisor, Niti Foundation, Nepal. [3] The panel was moderated by Dr. Constantino Xavier, Fellow, Foreign Policy and Security Studies, Brookings India. In attendance were over 100 participants from around the world who tuned in via Zoom and YouTube.COVID-19 (Disease);South Asia